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Abstract
Background: Limb-girdle muscular dystrophies are characterized by predominant involvement of the shoulder and
pelvic girdle and trunk muscle groups. Currently, there are 31 genes implicated in the different forms of limb-girdle
muscular dystrophies, which exhibit similar phenotypes and clinical overlap; therefore, advanced molecular
techniques are required to achieve differential diagnosis.
Methods: We investigated 26 patients from Latvia and 34 patients from Lithuania with clinical symptoms of
limb-girdle muscular dystrophies, along with 565 healthy unrelated controls from general and ethnic populations
using our developed test kit based on the Illumina VeraCode GoldenGate genotyping platform, Ion AmpliSeq
Inherited Disease Panel and direct sequencing of mutations in calpain 3 (CAPN3), anoctamin 5 (ANO5) and fukutin
related protein (FKRP) genes.
Results: Analysis revealed a homozygous CAPN3 c.550delA mutation in eight patients and three heterozygous
variants in controls: dysferlin (DYSF) c.5028delG, CAPN3 c.2288A > G, and FKRP c.135C > T. Additionally, three
mutations within FKRP gene were found: homozygous c.826C > A, and two compound – c.826C > A/c.404_405insT
and c.826C > A/c.204_206delCTC mutations, and one mutation within CLCN1 gene – c.2680C > T p.Arg894Ter. ANO5
c.191dupA was not present.
Conclusions: Genetic diagnosis was possible in 12 of 60 patients (20 %). The allele frequency of CAPN3 gene
mutation c.550delA in Latvia is 0.0016 and in Lithuania - 0.0029. The allele frequencies of CAPN3 gene mutation
c.2288A > G and DYSF gene mutation c.4872delG are 0.003.
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Background
Limb-girdle muscular dystrophies (LGMD) are a hetero-
geneous group of diseases that predominantly affect pel-
vic and shoulder girdle muscle groups. LGMD is a rare
disorder, and the different forms of LGMD range in
prevalence from 1 in 14,500 to 1 in 123,000, depending
on the population [1, 2]. The autosomal recessive form
of LGMD (LGMD type 2; LGMD-2) is more common,
with 23 causal genes and chromosomal loci identified to
date [3–7]. The rarer autosomal dominant (LGMD type
1; LGMD-1) form accounts for only 10 % of all cases
and has eight causative genes and chromosomal loci cur-
rently identified [6, 8, 9]. These genes encode proteins
involved in many different aspects of muscle cell biology.
Diagnosing of specific types of LGMD is a challenging
process due to the many genes involved, including un-
known genes within the identified chromosomal loci. Al-
though common mutations have been identified for
some causative genes (for example, calpain 3 (CAPN3)
c.550delA or fukutin related protein (FKRP) c.826C > A),
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a lot of additional mutations were found in different
populations. Confirming the diagnosis of LGMD, in
addition to subtyping, is usually done using molecular
techniques. Directly sequencing the coding regions of
the gene is the most common method, but remains often
insufficient, due to the size and number of genes in-
volved. Hence, the advancement of LGMD diagnostics
was achieved through next generation sequencing of the
genome or exome, or through targeted exome capture
applications. Furthermore, several commercially avail-
able kits include loci for the diagnosis of neuromuscular
disorders. The advantage of next generation sequencing
lies in the capability of analyzing whole exomes at a rea-
sonable cost without invasive muscle biopsies. Limita-
tions of this method are related to insufficient exon
coverage, leading to a potential lack of a representative
examination of all exons [10].
The aim of this study was to investigate LGMD type 2




We investigated 26 patients from Latvia and 34 patients
from Lithuania with clinical symptoms of LGMD. After
mutation identification, segregation analysis of the family
was performed.
Patients were recruited from the Neurology depart-
ment of Children’s University Hospital, from the out-
patient clinic for Neurological diseases at Pauls Stradins
Clinical University Hospital (Riga, Latvia), and from the
Center for Medical Genetics, Vilnius University Hospital
Santariskiu Clinics (Vilnius, Lithuania).
The Latvian patient sample consisted of 26 unrelated
individuals with predominant pelvic and shoulder girdle
muscle weakness and elevated creatine kinase (CK)
values. Patients with electromyography data demonstrat-
ing myopathy or myogenic impairment were included in
the study. A muscle biopsy was obtained from one pa-
tient; however, analysis of this was inconclusive regard-
ing their LGMD subtype. The mean patient age at the
onset of symptoms was 14 years (range: 1 month (acci-
dental finding without clinical symptoms until 8 years)
to 53 years), and the male:female ratio was 1.4:1.
The Lithuanian patient sample consisted of 34 unre-
lated patients with predominant pelvic and shoulder gir-
dle muscle weakness and elevated CK values. Mean
patient age at presentation was 23 years (range: 4–60
years) and the male:female ratio was 1:2.4.
The data collection was performed with permission
from the Central Medical Ethics Committee of Latvia.
All participants or their parents (in case of patient’s age
under 14 in Latvia and under 18 in Lithuania) signed an
informed consent forms to participate and publish.
Complete patient and family histories were taken at the
clinic, and patients were asked about their muscle
strength and performance before the onset of symptoms.
Patients were interviewed and examined by a neurologist
and a clinical geneticist experienced in neuromuscular
disorders.
Healthy, unrelated individuals (n = 204) randomly se-
lected from the Latvian Genome Database were used as
controls representing the general population. When ne-
cessary, we supplemented the study with 101 samples,
for total number of 394. Additionally, 175 DNA samples
from Lithuania and 186 samples from Latvia were used
as controls for ethnic groups. They were recruited, if
their ancestors from the last three generations could be
traced back archaeologically and ethno-linguistically to
distinct regions of Latvia and Lithuania [11, 12].
Microarray genotyping
We selected the highly parallel genome-wide VeraCode
GoldenGate system (Illumina, San Diego, CA, USA) as
the platform for mutation screening [13]. The main re-
sources used for manually selecting mutations, previously
published as causative for LGMD-2, were the open access
databases [14–17] as well as publications. Mutations were
selected based on their pathogenicity, location within
exons or splice sites, allele frequency, and the population
analyzed. In addition, the mutations had to satisfy the fol-
lowing criteria to comply with the VeraCode GoldenGate
system: they had to be single-nucleotide mutations (non-
synonymous single nucleotide polymorphisms (SNPs) or
insertions/deletions (indel)); diallelic (rather than triallelic
or tetra-allelic) to ensure allele specific hybridization, ex-
tension, and ligation; and be >60 base pairs away from any
other mutations on the array to prevent overlapping oligo-
nucleotides during hybridization. All LGMD patients and
general population controls were genotyped for the se-
lected mutation using a customized VeraCode Golden-
Gate system on a BeadXpress reader (Illumina). Reactions
and quality controls were carried out under the standard
conditions. To ensure quality control and to evaluate the
intra-subject concordance rate, 48 duplicate samples were
processed in one genotyping run, instead of 96 single
samples.
The presence of the identified mutations was con-
firmed by direct sequencing performed using standard
PCR conditions. The oligonucleotide sequences are
available upon request.
CAPN3 and anoctamin 5 (ANO5) mutation detection
The mutations in CAPN3 and ANO5 genes (c.550delA and
c.191dupA, respectively) in the Latvian and Lithuanian
populations were identified by direct sequencing performed
using standard polymerase chain reaction (PCR) conditions
(tannealing 56 °C) with the oligonucleotides CAPN3 F1 5’
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TCTCAAAAAGCACCCAGTCC 3’ and CAPN3 R1 5’
GCCTCTTCCTGTGAGTAGG 3’, and ANO5 F1 5’
TGGTATGTTTGCAGCATTTTTG 3’and ANO5 R1 5’
CATACCTCAAATTTTGGATGTTAC 3’.
The frequencies of mutations in the ethnic and general
populations were calculated using the Hardy-Weinberg
equation under the assumption of the absence of evolu-
tionary forces.
FKRP gene sequencing
A 1.7 kb fragment containing FKRP exon 4 and entire
coding sequence was amplified using previously published
primers [18] and 1.25 Units of Long PCR Enzyme Mix
(ThermoScientific, Lithuania). PCR conditions were as fol-
lows: 45 cycles, annealing temperature 52 °C, extension
temperature 68 °C, and DMSO concentration 4 %.
The exon 4 end exon-intron boundaries were ana-
lyzed by direct sequencing performed using published
[18] and following oligonucleotides: FKRP F1 5’AGAT
GCTGTGGTGCTCCTG 3’, FKRP R1 5’TCCAAGTA
GATGCCGAGGTC 3’, FKRP F2 5’AGCTGCTGGA
CTTGACCTTC 3’, and FKRP F2 5’CCCACGTCCTC
CAAGTAG 3’.
An automatic genetic analyzer (ABI PRISM 3130xl,
Applied Biosystems, Life Technologies, Carlsbad, CA,
USA) was used in all cases.
Next generation sequencing using AmpliSeq Inherited
Disease Panel
Life Technologies Ion Torrents targeted gene enrichment
and sequencing technology AmpliSeq was performed ac-
cording to a protocol provided by the manufacturer on
four patient samples.
The commercially available AmpliSeq Inherited Dis-
ease Panel (Life Technologies) that covers 325 gene
exons and intron-exon boundaries of most common
inherited diseases, including genes of LGMD and other
muscle dystrophies, was used for this approach [19].
Standard DNA extraction was followed by PCR amplifi-
cation using three primer pools included in the panel.
The amplicon mixes were combined and treated with
FuPa reagent (Life Technologies) to partially digest pri-
mer sequences and phosphorylate the amplicons, which
were then ligated to multiplexing barcodes (Life Tech-
nologies). Library was then purified using Beckman
Coulter (Nyon, Switzerland) AMPure XP magnetic
beads and amplified using PCR assay provided, followed
by another purification. Massive parallel sequencing of
library created was done using Ion Torrent PGM device.
Results
A total of 264 DNA samples, 26 from Latvian patients,
34 from Lithuanian patients, and 204 healthy controls,
were analyzed by a custom microarray for the selected
loci.
We initially selected 209 sequence’s variants based on
the criteria mentioned above. Of these, 121 were muta-
tions in the CAPN3 gene, 50 were mutations in dysferlin
(DYSF), 28 were mutations in sarcoglycan alpha (SGCA),
sarcoglycan beta (SGCB), sarcoglycan delta (SGCD), and
sarcoglycan gamma (SGCG), two were gender controls
(amelogenine, X-linked/ amelogenine, Y-linked), and
eight were control polymorphisms. This initial number
of mutations was reduced considerably due to designs
resulting in critical failure scores, as calculated by the
Assay Design Tool. To increase the overall performance
and sensitivity of the assay, we had to decrease the in-
vestigated variants to a final total of 96.
Data cleaning was completed as recommended by the
manufacturer resulting in exclusion of 23 samples.
In addition, we did a “paired sample” test in the final
quality control step to compare the call frequency values
of the duplicate samples, which led to the classification
of 13 additional mutations as false positives and decrease
the analyzed sample size to 185 (80 %). Additional file 1:
Table S1 contains information about quality the parame-
ters. A complete list of the Group 1 mutations, which
have the best test performance (n = 20) is provided in
Additional file 1: Table S2A. The additional mutations
with fluctuating results included in the test (n = 57) form
Group 2 and are provided in Additional file 1: Table S2B.
Excluded mutations are provided in Additional file 1:
Table S2C. After cleaning the data, we identified four dif-
ferent mutations in our cohort of patients and controls.
Our analysis revealed the c.550delA homozygous muta-
tion in CAPN3 in eight Lithuanian cases (24 %). Controls
from the Latvian population did not have CAPN3
c.550delA, but had two causative mutations: DYSF
c.4872delG and CAPN3 c.2288A > C, and one benign SNP
FKRP c.135C > T (one heterozygous allele each; see
Table 1). These three variants were not detected in pa-
tients. Re-sequencing of these mutations revealed one
false negative case within the data from the Illumina Vera-
Code GoldenGate assay. Thus, the sensitivity of the test
was 89 % (95 % confidence interval (CI): 0.54–0.99), and
the specificity was 98 % (95 % CI:0.89–0.99).
Because no controls had the CAPN3 c.550delA muta-
tion, it was not possible to estimate the frequency of this
allele in the populations. For estimating its allele fre-
quency in the Latvian population, an additional 101 indi-
viduals were selected from the Latvian Genome
Database. One heterozygous carrier was found, and they
had no symptoms of neuromuscular disease. Thus, the
allele frequency of c.550delA within the Latvian popula-
tion is estimated to be 0.0016 (0.16 %). However, the
situation was different in the Lithuanian samples, in
which the c.550delA allele was found in one of 175
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samples, making the calculated allele frequency 0.0029
(0.29 %). Using the Hardy-Weinberg equation, the esti-
mated number of persons homozygous for CAPN3
c.550delA in the Latvian population is 0.3 per 100,000
persons, and in the Lithuanian population, it is 0.8 per
100,000. Other three variants DYSF c.4872delG, CAPN3
c.2288A > C, and FKRP c.135C > T had an allele fre-
quency of 0.3 % in Latvian population, and the calcu-
lated number of homozygous persons was 1 in 166,000
for each of them.
Data from patients who had been diagnosed with
LGMD2A using the GoldenGate VeraCode assay, were
summarized. Information about these patients’ clinical
symptoms is in Table 2. To further ensure our results,
we performed mutation analysis in the patients’ families,
and confirmed mutations in two affected siblings. The
segregation analysis was concordant with the clinical
picture and the presence of the mutation.
As a recent and population-specific finding, mutation
c.191dupA of the ANO5 gene was also analyzed in pa-
tients and ethnic control groups because of its reported
frequency in North European populations [20]. Analysis
did not reveal the variant in any of the samples, resulting
in an allele frequency of zero in Latvia and Lithuania.
Since none of selected mutations were found within
Latvian patients’ samples, we performed analysis by dir-
ect sequencing of entire coding region and 4th exon-
intron boundaries of FKRP gene for 23 Latvian patients.
Table 2 Description of patients with identified mutations
Gene Patient ID Mutation Symptoms
FKRP c.826C>A/c.826C>A Female, disease onset at age 11, shoulder girdle muscle weakness and atrophy, pseudohypertrophy
of calves, hyperlordosis, respiratory difficulty, CK level (U/l) 700-1500
FKRP c.826C>A/c.404_405insT Male, disease onset at age 5 with rhabdomyolysis, hypertrophic cardiomyopathy, hypertrophy of
calves, mild proximal weakness, Gowers’ symptom negative, CK level (U/l) 32,000
FKRP c.826C>A/c.204_206delCTC Female, age 8, slight proximal muscle weakness, CK level (U/l) 700
CLCN1 c.2680C>T/N Female, disease onset at age 4, severe proximal muscle weakness, Gowers’ symptom positive,
myotonia by EMG, CK level (U/l) 13,059
CAPN3 D06 c.550delA/c.550delA Female, disease onset at age 4, tip toe walking, proximal muscle weakness and atrophy, scoliosis at
age 10, ankle and elbow contractures in teen years, significantly reduced physical activity at age 19,
still walking after 34 years from onset, CK level (U/l) 4000 at present.
CAPN3 D07 c.550delA/c.550delA Female, disease onset at pre-school age, walking and gait disorders, proximal muscle weakness and
atrophy, CK level (U/l) 9001
CAPN3 D08 c.550delA/c.550delA Female, disease onset at age 11, tip toe walking, waddling gait, frequent falling and inability to run,
scapular winging, hypertrophy of calves, still walking after 16 years from onset, CK level (U/l) 5722
CAPN3 D09 c.550delA/c.550delA Female, disease onset at age 7 with history of frequent falling and inability to run, short stature,
hypertrophy of calves, proximal muscle weakness, scapular winging, walking with assistance at the
age 17, CK level (U/l) 4000
CAPN3 D10 c.550delA/c.550delA Female, disease onset at age 6, muscle weakness and atrophy in the lower extremities with difficulty
running, climbing stairs, and frequent falls, waddling gait, scoliosis, dependent on a wheelchair at
age 17, CK level (U/l) 18,826
CAPN3 D16 c.550delA/c.550delA Male, disease onset at age 14, pes equinovarus from birth, waddling gait, fatigue in his arms
progressively worsened to symmetric weakness in hip girdle, scapular winging, walking with
assistance at age 29, dependent on a wheelchair at age 32, CK level (U/l) 6370
CAPN3 D23 c.550delA/c.550delA Female, disease onset at age 7, proximal muscle weakness, still walking after 34 years from onset,
CK level (U/l) 7487
CAPN3 D24 c.550delA/c.550delA Male, disease onset at age 3, tip toe walking, proximal muscle weakness, hypertrophy of calves,
significant loss of physical activity at age 14, CK level (U/l) 854
CK, creatine kinase, EMG, electromyography
Table 1 Mutations identified with LGMD-2 diagnostic test kit
Name Gene Mutation Frequency in Control group Frequency in the group
of patients with NMD
Known mutation frequency
CAPN3_00010 (rs80338800) CAPN3 c.550delA 0 (0.001a) 0.13 NA
CAPN3_00119 CAPN3 c.2288A>C 0.003 0 NA
DYSF_00178 DYSF c.4872delG 0.003 0 NA
rs2287717 FKRP c.135C>T 0.003 0 0.14
afrequency estimated for enlarged control group (with additional 101)
NA, data not available
NMD, neuromuscular disorders
Inashkina et al. BMC Musculoskeletal Disorders  (2016) 17:200 Page 4 of 6
26 Lithuanian patients, who had not been diagnosed
with LGMD2A, were also included in this analysis. Our
analysis revealed one c.286C > A homozygous mutation
in Lithuanian patient and two compound heterozygous
mutations (one in each of Lithuanian and Latvian case)
within the coding region of FKRP gene. The first is
FKRP c.826C > A/c.404_405insT mutation, unknown cis
or trans position, another one is FKRP c.826C > A/
c.204_206delCTC in trans position that is confirmed by
segregation analysis, carried out in the patient’s parents
samples. Information about patients’ clinical symptoms
is summarized in Table 2.
Additionally, next generation sequencing using Ampli-
Seq Inherited Disease Panel was performed on four pa-
tient samples. These patients had no diagnosis found by
other methods described. One heterozygous mutation
within chloride voltage-gated channel 1 (CLCN1) gene –
c. 2680C > T p.894R > X was identified. Patients’ clinical
features are described in Table 2.
Discussion
This study, using the LGMD-test kit, revealed a homozy-
gous CAPN3 c.550delA mutation in eight Lithuanian pa-
tients and three variants (one heterozygous allele each)
in controls: DYSF c.5028delG, CAPN3 c.2288A > G (both
were reported as pathogenic), and FKRP c.135C > T (be-
nign polymorphism). These three variants were not de-
tected in patients.
The mutation CAPN3 c.550delA is one of the most
frequent among patients suffering from LGMD-2. It has
been identified in many countries, including France,
Greece, Italy, the Netherlands, Germany, and the United
Kingdom, but was relatively infrequent in these popula-
tions [21, 22]. Relatively high frequencies (40–70 % of
LGMD2A cases) of CAPN3 c.550delA have been ob-
served and reported in Turkey, Bulgaria, Croatia, the
Czech Republic, Poland, and Russia [23–29]. Canki-
Klain et al. suggested that the CAPN3 c.550delA muta-
tion originated in the Eastern Mediterranean, probably
spreading widely across Europe, and single haplotype
analysis confirms this hypothesis [27].
Our data suggest that CAPN3 c.550delA is also the
most frequent mutation in LGMD patients in Lithuanian
populations. The calculated frequency of homozygous
persons is 0.8 per 100,000 people, and in Latvia calcu-
lated frequency is 0.3 in 100,000. The marked difference
observed between allele frequencies in Lithuanian and
Latvian populations remains unexplained. We speculate
that the disease gradient falls rapidly towards the North
and East of Europe.
The CAPN3 gene mutation c.2288A > G and DYSF
gene mutation c.5028delG (currently c.4872delG) carrier
frequency is 1 in 204 people.
We did not find common mutations in ANO5, SGCA,
SGCB, SGCD, or SGCG. It is possible that these com-
mon mutations have distinct founder effects and are
sparsely scattered in Northeast Europe.
Additionally, we found three different mutations
within FKRP gene: c.826C > A, c.404_405insT, and
c.204_206delCTC and one mutation in CLCN1 gene –
c.2680C > T.
Currently, the LGMD-2 diagnosis toolkit is not vital
for diagnostics; nevertheless, the information about the
mutation spectrum we acquired in this study is import-
ant for construction a gene panel for LGMD diagnostics
and gives insight into the mutation spectrum of this het-
erogeneous disease.
Conclusions
The LGMD-2 test kit was introduced as a rapid and low
cost screening tool for improvement of the healthcare of
the neuromuscular disease patients. Genetic diagnosis
was achieved in 12 of 60 patients (20 %). The allele fre-
quency of CAPN3 gene mutation c.550delA in Latvia is
0.0016 and in Lithuania – 0.0029. The allele frequencies
of CAPN3 gene mutation c.2288A > G and DYSF gene
mutation c.4872delG are 0.003 in Latvia and profiled the
known common mutations causing LGMD-2.
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